Background: Gangliosides are enriched in the neuronal membranes. Gangliosides are shown to interact with amyloid-β proteins, leading to formation of amyloid fibrils in Alzheimer's disease (AD) brains. Several earlier studies indicated that the alterations of ganglioside metabolism could contribute the pathogenesis of AD.
Methods: Gangliosides were isolated from the frontal lobes in five patients with AD and three control subjects. Gangliosides were assessed by high performance thinlayer chromatography (HPTLC) with resorcinol staining and immunostaining using mouse monoclonal antibodies against cholinergic neuronspecific (Chol-1α) gangliosides.
Results:
In all AD brains, not only the total sialic acid content but also a-series gangliosides, GM1 and GD1a, were dramatically reduced as compared with those in control subjects. These results are a hallmark of the pathogenesis in AD. In contrast, Chol-1α gangliosides, GT1aα and GQ1bα, which are specific markers of cholinergic neurons, were significantly increased in AD brains.
Conclusion:
The expression of Chol-1α gangliosides may be caused by a compensation to preserve the function of the cholinergic neuron and play an important role in cholinergic synaptic transmission. (A) In AD brains, the total lipid-bound sialic acid (NeuAc) content was significantly reduced as compared with those of control subjects. (B) High-performance thin-layer chromatogram (HPTLC) of gangliosides developed with a solvent system of chloroformmethanol-0.2% calcium chloride (50:45:10, by volume). Lane 1, bovine brain ganglioside mixture; lanes 2 and 3, gangliosides from control subjects; lanes 4 and 5, gangliosides from patients with AD; lanes 6 and 7, authentic samples of gangliosides. (C) The overall contents of each ganglioside were reduced in patients with AD, especially for GM1 and GD1a as compared with those of control subjects. The values were represented as μg of each gangliosides per g of wet weight of tissues.
METHODS & RESULTS

Fig 3. Expression of cholinergic neuron-specific gangliosides.
(A) High-performance thin-layer chromatogram plates were immunostained with monoclonal antibody to GT1aα and GQ1bα. Lanes 1 to 3, gangliosides from control subjects; lanes 4 to 8, gangliosides from patients with Alzheimer's disease (AD); lanes 9 to 11, authentic samples of GT1aα and GQ1bα (10, 20 and 30 ng, respectively) . (B) In AD brains, the contents of GQ1bα and GT1aα were significantly elevated as compared with those of control subjects.
AIM
To investigate the change of specific ganglioside metabolism and expression of Chol-1α gangliosides in the brains of patients with AD. 
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Alzheimer's disease (AD) is characterized by degeneration of the cholinergic neurons in the basal forebrains and ensuing deficient cholinergic functions in cortex and hippocampus, leading to cognitive and behavioral problems. Several earlier studies have pointed out that the concentrations of gangliosides which are abundant in the neuronal membranes decreased in the brains of patients with AD, and the pattern of specific gangliosides was significantly changed in defined regions of the brains . The changes of patterns of ganglioside expression and their levels were closely related to their metabolism, particularly their biosynthesis (Fig. 1) .
Conclusion
The cholinergic neuron-specific gangliosides are strongly expressed in the brains of patients with AD, which may be caused by compensation to preserve the function of the cholinergic neurons. The change of gangliosides metabolism in the brains of patients with AD could be lead to a diagnostic marker and treatment of Chol-1α gangliosides may be therapeutic target to combat the cognitive defects seen in AD. We previously reported that Chol-1α antigens (cholinergic neuronspecific gangliosides), such as GT1aα and GQ1bα, which are minor species in the brains, were found to be increased in the doubletransgenic mouse brains expressing mouse/human chimeric amyloid precursor protein (APP) with the Swedish mutation and human presenilin-1 (PS-1) with a deletion of exon 9 (APP/PS-1). We interpreted that the occurrence of these gangliosides might represent evidence for generation of cholinergic neurons in AD brains, as a result of compensatory neurogenesis activated by the presence of amyloid β protein (Ariga T et al, ASN Neuro 2010, ASN Neuro 2013). Chol-1α gangliosides are developmentally expressed in rat brain and hippocampus, the upregulation of the expression of Chol-1α gangliosides in the brains of AD model of mouse may be a compensatory mechanism for the underlying age related decline of cholinergic function in AD.
